

CONGENITAL ABSENCE OF SKIN ON THE RIGHT LEG AND NAIL ABNORMALITIES-EPIDERMOLYSIS BULLOSA OR BART'S SYNDROM ?

Marina Stanojević¹, Katarina Čuković Prokić¹, Dragana Savić^{1,2}, Biljana Vuletić^{1,2}, Anđelka Stojković^{1,2}, Sanja Knežević^{1,2},
Katerina Dajić¹, Jelena Ceković¹ and Aleksandra M. Simović^{1,2}

¹Clinical Center Kragujevac, Pediatric Clinic, Kragujevac, Serbia

²University of Kragujevac, the Faculty of Medical Sciences, Department of Pediatrics, Kragujevac, Serbia

UROĐENI NEDOSTATAK KOŽE NA DESNOJ NOZI I ABNORMALNOST NOKATNE PLOČE - BULOZNA EPIDERMOLIZA ILI BARTOV SINDROM?

Marina Stanojević¹, Katarina Čuković Prokić¹, Dragana Savić^{1,2}, Biljana Vuletić^{1,2}, Anđelka Stojković^{1,2}, Sanja Knežević^{1,2},
Katerina Dajić¹, Jelena Ceković¹, Aleksandra M. Simović^{1,2}

¹ Klinički centar Kragujevac, Pedijatrijska klinika, Kragujevac, Srbija

² Univerzitet u Kragujevcu, Fakultet medicinskih nauka, Odeljenje za pedijatriju, Kragujevac, Srbija

Received/Primljen: 12.03.2019.

Accepted/Prihvaćen: 18.06.2019.

ABSTRACT

Children born with the epidermolysis bullosa (so-called "butterfly children") can eat only liquid or soft food due to the blisters on their mouth, tongue and esophagus. Due to their inactivity and permanent wounds, their fingers are curved and grown with a fist. Their eyes, anus and genitals are not spared either. The digestion is usually poor, so they often suffer from the constipation, and sometimes the intestine discharge can be performed only surgically. Due to frequent and numerous wounds, infections may develop, which can lead to sepsis. Wounds are caused by any kind of the pressure and re-bandaging of wounds is the most painful. These children can later be susceptible to other diseases, especially the skin cancer. More than 80% of children diagnosed with this disease become disabled in the first years of their lives, and some of them pass away immediately after birth. The average lifespan of the diseased is about 28 years. Here we have presented a rare case of a newborn male infant with a dystrophic epidermolysis bullousa, a congenital skin aplasia on the right leg and a nail dystrophy. Based on a typical clinical presentation, we think that it is Bart's syndrome.

Keywords: epidermolysis bullosa, "butterfly children", Bart's syndrome

SAŽETAK

Deca rođena sa buloznom epidermolizom (takozvana „deca leptiri“) mogu da jedu samo tečnu ili kašastu hranu zbog plikova na ustima, jeziku i jednjaku. Zbog neaktivnosti i stalnih rana prsti im se krive i srastaju sa šakom. Nisu pošteđene ni oči, analni otvor i genitalije. Varenje je obično loše, pa često imaju opstipaciju, a ponekad se pražnjenje creva može izvršiti samo hirurški. Usled čestih i mnogobrojnih rana, dolazi do infekcija koje mogu dovesti do sepse. Rane izaziva svaka vrsta pritiska, a najbolnije je previjanje. Ova deca su kasnije podložnija drugim bolestima, a posebno karcinomu kože. Preko 80% obolelih postaju invalidi već u prvim godinama života, a neki od njih umiru neposredno po rođenju. Prosečan životni vek obolelih je 28 godina. U ovom radu smo predstavili redak slučaj muškog novorođenčeta sa distrofičnom buloznom epidermolizom, urođenom aplazijom kože na desnoj nozi i distrofijom nokta. Na osnovu tipične kliničke prezentacije mislimo da je u pitanju Bartov sindrom.

Ključne reči: bulozna epidermoliza, „deca leptiri“, Bartov sindrom



INTRODUCTION

Epidermolysis bullosa (EB) is an inherited mechano-bullous disorder characterized by skin fragility and blister formation, following minor trauma or traction on the skin. Children born with the EB are commonly referred to as “butterfly children” due to their skin being so fragile it mimics a butterfly wing. The EB encompasses many clinically distinctive phenotypes: the EB simplex (EBS), the junctional EB (JEB), the dystrophic EB (DEB) and the Kindler syndrome (KS). The EBS was further separated into suprabasal and basal subgroups, based on the histopathologic site of cleavage within the epidermis. (1, 2)

As a correlate, the presence of diagnostically useful skin findings (e.g. exuberant granulation tissue, mottled pigmentation, pseudosyndactyly and other) may permit further subclassification at this level. Each patient then can be further subclassified on the basis of a mode of transmission and, if identifiable, by the specific gene involved, the latter initially determined by means of immunohistochemical techniques (IFM, using EB-pertinent monoclonal antibodies) and later by the mutation analysis. In some clinical settings, some EB investigators prefer to pursue molecular screening without first obtaining of IFM results. The EB can be inherited in the dominant or recessive form, it can also arise as a spontaneous mutation where neither parent carries EB or is physically affected by the condition. The gene mutation occurs spontaneously in the sperm or egg before conception. (1, 3)

The overall prevalence of EB has been estimated to be about 1 in 100,000 in Italy, 1 in 130,000 in the United States, 1 in 20,000 in Scotland and in Croatia it is 9.6 cases per million live births. The number of the diseased in Serbia is still unknown, but according to the latest data there are about 140. The incidence and prevalence of dominant DEB were found to be 2.12 and 1.49 cases per 1 million live births and recessive DEB were found to be 3.05 and 1.35 cases per 1 million live births. (4, 5)

In our case, the clinical finding of DEB, the Aplasia Cutis Congenital (ACC) and nail dystrophy shows that it is Bart’s syndrome, first described by Bruce J. Bart in 1966. Bart’s syndrome is usually diagnosed based on the clinical presentation. In some cases, the analysis may require skin biopsy to determine the type of epidermolysis bullosa and genetic study to look for the exact gene mutation that may help to confirm the final diagnosis. (6)

CASE REPORT

A term newborn male delivered by Caesarean section (C-section) after an uncomplicated pregnancy and spontaneous rupture of membranes approximately 32 hours prior to delivery. Apgar score was 8 at 5 minutes. The baby’s weight was 2780 g and the head circumference was 33 cm. Upon initial physical examination, the patient was presented with multiple skin defects: on the anterior side of the lower third of the upper leg, knee, lower leg and whole feet, on the dorsal parts

of the fist and fingers, on the head skin frontal and temporal right, in the area of the upper lip and right hemithorax. (Picture 1.)

Picture 1. Appearance of the newborn after birth



These defects were dark red color, dry and slightly deeper on the right leg with visible vascularization. Also, there were rarely collapsing blisters. On the front of the right leg, including the knee, foot dorsum, thumb and right-foot sole, the complete absence of the skin, peripheral with the individual haemorrhagic blisters. The nail plate on the right foot is missing. Haemorrhagic blisters were present on some finger nails and toes of the fist and feet. (Picture 2.)

Picture 2. Congenital localized absence of skin, blistering of the skin and absence of nail plate on the right foot



Other physical findings were normal for the age. Baby was transferred to the Neonatal Intensive Care Unit (NICU), on the first day of life.

In the NICU, the intravenous catheter for rehydration was placed to prevent dehydration from extended evaporation from the skin and for initial dual antibiotic therapy (cefotaxime - Tolycar[®] and vancomycin) to prevent infection. The inflammation parameters were elevated, the C reactive protein was 23 mg/L, while procalcitonin was 4.450 ng/ml. Blood and urine results were normal for the age. Abdominal and cranial ultrasound imaging, and echocardiography revealed normal findings. Bacteriological analysis of eye swabs, nasal swabs and erosion swabs (axillary region, knees, fists, right upper arm and knee) have shown normal flora. He received phenobarbitone due to sedation and acetaminofene (Paracetamol[®]) as an analgesic. The skin was treated according to a Dermatologist's advice (bandage once a day, 1% chloramphenicol unguent daily on skin defects). After four days, the patient was transferred to the Clinical Center of Serbia (CCS), Pediatric department, for further treatment and examination. A Dermatologist's physical examination in the CCS has also identified a variety of skin changes and congenital aplasia of the skin on the right leg and foot and nail dystrophy.

Topical treatment for all erosion was 0,1% gentamicin unguent, and than wrapping with sterile gauze (Mepilex[®] Transfer gauze) and bandaging soaked with vaseline once a day and for eyes 1% chloramphenicol unguent daily. Skin zones with residual changes and without erosion were treated with emollients once a day. For erythema on the face 1% hydrocortison unguent was used twice per day and for erythema in the diaper region miconazole (Dactanol[®]) gel several times per day. Regarding skin care and daily bathing, oil bath (Lipikar syndet baby[®]) and nonadhesive re-dressing were prescribed. The substitution of vitamin D 500 IU./mL was recommended once per day. After 3 weeks, the erosion was in the final phase of epithelialization. The zone of congenital skin absence on the right lower leg was in the final phase of epithelialization. The erythema on the face was significantly bleached. (Picture 3.) The general condition was well and the mother was given detailed instructions about handling the baby and continuing with the local wound care. Further therapy was performed by 0,1% gentamicin unguent and emollients and bandage Mepilex[®] Transfer gauze and separation of fingers by Mepilex[®].

In the fourth month of life the child was diagnosed with Dermatitis atopica, the child has the highest number of erosions on the face and ear shells with eczema and itching. After 1% hydrocortison unguent therapy for 7 days, the child had an erythema with white squamous on cheeks. Levocezirizine (Xyzal[®]) 0,5 mg/ml oral solution was recommended twice a day for 2.5 ml in the case of itching and eczema exacerbation.

Picture 3. After topical treatment in the final phase of epithelialization



DISCUSSION

The EB is a very rare disease, especially in the form of congenital skin aplasia. In previous studies, it has been shown that the EB manifestation is not only limited to the skin. Systemic signs might involve the nose, ear, eye, genitourinary tract and upper gastrointestinal tract. A. Michalak et al. have described in their work that gastrointestinal manifestation of the EB is most commonly reflected by esophageal stenosis due to recurrent esophageal blistering, followed by consequent scarring. (7) Also, in study of nine cases with the Congenital Pyloric Atresia (CPA), M.Kansra et al. had one patient with the CPA (type 3) and the ileal atresia associated with the EB. (8) In our case the EB is in combination with congenital skin aplasia, which is based on the author Frieden, in 6th group and it is called Bart's syndrome. The inheritance pattern of Bart's syndrome appears to be an autosomal dominant. Nevertheless, several sporadic cases have been reported. Bart's syndrome is considered as an exceedingly rare genetic disorder. (9) Our case of Bart's syndrome presented with the classic triad of congenital localized absence of skin over right lower leg, blistering of the skin, and absence of nail plate on the right foot.

When evaluating newborns with plaques and/or erosion, in addition to numerous diagnostic conditions, the EB should be taken into consideration. The differential diagnosis for blisters in a neonate is extensive and includes common acquired etiologies such as sucking blisters or other birth trauma-induced blisters, infection-related blisters such as the herpes simplex, the bullous impetigo, the staphylococcal scalded skin syndrome, the neonatal candidiasis, the neonatal varicella; maternal autoimmune bullous conditions such as the bullous pemphigoid (can also appear de novo), the pemphigoid gestationis or the pemphigus vulgaris; others such as a bullous aplasia cutis congenita, and bullous mastocytosis; and genetic disorders including the incontinentia pigmenti, the ectodermal dysplasia, the epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma), the pachyonychia congenita, the congenital erosive dermatosis with

reticulated supple scarring and the epidermolysis bullosa (all subtypes). (2) Analogous to peeling an onion, Jo-David Fine et al. suggested that the classification and subclassification of patients with the EB begin with their separation into 1 of 4 main EB groups, based on the level (intraepidermal [EBS]; within [JEB] or beneath [DEB] the skin basement membrane zone (BMZ); or mixed pattern [Kindler syndrome]) within which blisters develop. In EB simplex (EBS) suprabasal, the blisters form within the middle/upper epidermal layers, depending on which protein is mutated. In the EBS basal, the cleavage plain is within the basal keratinocytes. In junctional EB (JEB), the separation takes place within the lamina lucida, and in dystrophic EB (DEB), within the sublamina densa region within the uppermost dermis. In the fourth type cleavage it can occur within the basal keratinocytes, at the level of the lamina lucida or below the lamina densa and it is Kindler syndrome [KS], mixed pattern. Further, intraepidermal EBS is divided into two groups: suprabasal and basal EBS. Targeted proteins by the gene mutation in suprabasal EBS are Transglutaminase 5 (TGM5), plakophilin 1 (JUP), desmoplakin (DSP) and plakoglobin (PKP1); in basal EBS are keratins 5 or 14 (KRT5, KRT14), plectin (PLEC), exophilin 5 Slac2-b (EXPH5) and bullous pemphigoid antigen 1 (DST). Changes in JEB are in intralamina lucida and in the generalized form affected proteins are: laminin-332 (LAMA3A), collagen XVII (COL17A1), $\alpha 6\beta 4$ integrin (ITGB4, TGA6), $\alpha 3$ integrin subunit; in localized form: collagen XVII, laminin-332, $\alpha 6\beta 4$ integrin. In DEB only collagen VII (COL7A1) is affected. (1, 10) The next level of subclassification takes into account the clinical phenotypic features present in a given patient, most notably the distribution (localized vs generalized) and the relative severity of cutaneous and extracutaneous disease involvement. Ensuring that the correct treatment plan and dressing regimen are implemented with EB patients is challenging due to painful open wounds and the exceptionally fragile skin.

CONCLUSION

Epidermolysis bullosa is a rare, hereditary, non-contagious, but still incurable disease. The average lifespan of the diseased is shortened, requiring constant care and complete dependence on other people.

REFERENCES

1. Fine, J. D., Bruckner-Tuderman, L., Eady, R. A., Bauer, E. A., Bauer W. J., Has, C., Heagerty, A., Hintner, H., Hovnanian, A., Jonkman, M. F., Leigh, I., Marinkovich, M. P., Martinez, E. A., McGrath, A. J., Mellerio, E. J., Celia, M., Murrell, D. F., Shimizu, H., Uitto, J., Woodley, D. & Zambruno, G. (2014). Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. *J Am Acad Dermatol.* 70(6), 1103-1126. DOI: 10.1016/j.jaad.2014.01.903.
2. Gonzalez, M. E. (2013). Evaluation and treatment of the newborn with epidermolysis bullosa. *Seminars in perinatology* 37(1), 32–39. DOI: 10.1053/j.semperi.2012.11.004.
3. Lynne, V., Burns, L., Handsaker, J. & Murdoch J. M. (2018). Epidermolysis bullosa: management complexities for paediatric patients. *Br J Nurs.* 27(12), 20-25. DOI: 10.12968/bjon.2018.27.Sup12.S20.
4. Fine, J. D. (2016). Epidemiology of Inherited Epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry. *JAMA Dermatol.* 152(11), 1231-1238. DOI: 10.1001/jamadermatol.2016.2473.
5. Wiss, K. (2001). Epidermolysis bullosa: Clinical, epidemiologic, and laboratory advances and the findings of the National Epidermolysis Bullosa Registry. *J Am Acad Dermatol* 44 (5). 882. DOI: [https://doi.org/10.1016/S0190-9622\(01\)70199-5](https://doi.org/10.1016/S0190-9622(01)70199-5).
6. Bart, B. J., Gorlin, R. J., Anderson, V. E. & Lynch, F. W. (1966). Congenital localized absence of skin and associated abnormalities resembling epidermolysis bullosa. A new Syndrome. *Arch Dermatol.* 93(3). 296-304. DOI:10.1001/archderm.1966.01600210032005
7. Michalak, A., Cichoż-Lach, H., Prozorow-Król, B., Buk, L. & Dzida, M. (2018). A rare case of skin blistering and esophageal stenosis in the course of epidermolysis bullosa - case report and literature review. *BMC Gastroenterol.* 18(1), 47. DOI: 10.1186/s12876-018-0771-5.
8. Kansra, M., Raman, V. S., Kishore, K., Khanna, S., Puri, B. & Sharma, A. (2018). Congenital pyloric atresia - nine new cases: Single-center experience of the long-term follow-up and the lessons learnt over a decade. *J Pediatr Surg.* 53(11), 2112-2116. DOI: 10.1016/j.jpedsurg.2018.04.015.
9. Chen, Z., Bu, W., Feng, S. & Wang, H. (2018). Bart's syndrome in a family affected three consecutive generations with mutation c.6007G>A in COL7A1. *J Dermatol.* 45(8), 1000-1002. DOI: 10.1111/1346-8138.14352.
10. van den Akker, P. C., van Essen, A. J., Kraak, M. M., Meijer, R., Nijenhuis, M., Meijer, G., Hofstra, R. M., Pas, H.H., Scheffer, H. & Jonkman, M.F. (2009). Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations. *J Dermatol Sci.* 56(1), 9-18. DOI: 10.1016/j.jdermsci.2009.06.015.



INSTRUCTION TO AUTHORS

Serbian Journal of Experimental and Clinical Research is categorized as M51 on the list of categorized national scientific journals of the Ministry of Education, Science and Technological Development of the Republic of Serbia.

Serbian Journal of Experimental and Clinical Research only publishes papers that have not been previously published. Any attempt of plagiarism or self-plagiarism shall be penalized (publication of papers is banned to all authors for a certain period of time depending on the degree of plagiarism and the management of the institutions in which the authors work are informed about this, as well as their professional associations).

Only papers written in English are accepted, with the title, affiliations, abstracts and keywords both in Serbian and English.

Since the Journal has started with electronic editing and publication of papers sent to the address: <https://www.editorialmanager.com/sjocr/default.aspx>, all papers are submitted to the Editorial Board in this way EXCLUSIVELY.

All authors, reviewers and editors must be registered system users with a unique e-mail address. Authors can register via the link: <https://www.editorialmanager.com/sjocr/default.aspx>.

Technical instruction to use the e-UR system: electronic editing of papers can also be accessed at: <http://www.editorialmanager.com/sjocr/>.

When submitting the paper to the electronic editing system *SerJExpClinRes*, it is necessary to enclose a statement that all technical requirements have been met, including a statement signed by all authors and co-authors that the paper has not been published, in whole or in part, or accepted for publishing in another journal. The statement on the individual contribution of the author has to be signed by each author of the paper, scanned and sent as a supplementary file (requested in the system as Cover Letter). Also, the authors are obliged to submit a signed statement on non-existence of conflict of interest. By this procedure, all authors become responsible for meeting all set requirements, followed by the decision on acceptance for further editorial procedure. The system of journal electronic editing *Editorial Management* includes the use of the CrossCheck service, so all the papers are automatically checked to plagiarism or self-plagiarism, prior to the first step of the editorial process.

Accepted papers are published in the order determined by the Editorial Board on the suggestion of Editor-in-Chief. *SerjexpClin* publishes exclusively: original articles, review papers and case reports.

Each original scientific paper and case report has to contain the following parts: ABSTRACT, INTRODUCTION, THE AIM OF THE PAPER, PATIENTS AND METHODS, RESULTS, DISCUSSION, CONCLUSION and REFERENCES. Review paper does not necessarily have to contain all stated segments; it can have an independent structure.

Times New Roman font 10pt is used for manuscript writing, and a new paragraph is indented for better visibility.

Submitted papers are first forwarded to the editor, and then to, at least, two reviewers. Comments and suggestions of the editor and reviewers (without the names of the reviewers) are delivered to the author for final modification of the paper.

After professional and editorial processing and before publishing, the accepted paper is referred to the corresponding author for authorial reading. At this stage, it is not possible to make major changes, but only to correct letters and other minor mistakes. If the corrected text is not returned within seven days, it will be considered that the author has no objections.

Upon editor's approval, after received positive paper reviews, the paper is accepted in the system, and the corresponding author receives information about the paper accepted for publication to the email address.

DOI number is assigned to the paper and, after proofreading and text break according to the Journal instructions, the paper is published as Ahead of Print first on the Journal page at Sciendo platform: <https://content.sciendo.com/view/journals/sjocr/ahead-of-print/issue.xml> and then in one of the next issues of the Journal.

All papers, regardless of the source language, are cited in English, and the source language is stated in brackets, after the title. We do not accept citation of abstracts, secondary publications, oral presentations, unpublished papers, official and confidential documents. Citation of papers accepted for publication, in the procedure of preparation for printing, can be accepted by stating the title and putting *in press* in brackets after the name of the journal.

The examples of correct referencing:

For journal papers:

e. g. Shoji F, Haro A, Yoshida T, Ito K, Morodomi Y, Yano T, et al. Prognostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. *Ann Thorac Surg* 2010; 89(3): 864–9.

For books:

e. g. Kleiner, F.S., Mamiya C.J. & Tansey R.G. (2001). *Gardner's art through the ages* (11th ed.). Fort Worth, USA: Harcourt College Publishers.


For conference papers:

e. g. Field, G. (2001). Rethinking reference rethought. In *Revealing in Reference: Reference and Information Services Section Symposium*, 12-14 October 2001 (pp. 59-64). Melbourne, Victoria, Australia: Australian Library and Information Association.



GUIDE TO PREPARING FIGURES

Figure and legend must fit within this box



FILE FORMATS

We prefer ai, eps, pdf, svg, layered psd, tif and jpg files. Please submit each figure as an individual file separate from the manuscript text.

FIGURE LAYOUT AND SCALING

We will use your suggested layout as a guide, but it may be necessary to rearrange or change the size of your figures because of production constraints.

When laying out your figure:

- Avoid wide variation in type size within a single figure.
- Maximize the space given to the presentation of the data.
- Avoid wasted white space.

LABELS

All text should be in a typeface Times New Roman.


- Panel parts are 10 point Bold **A B C D**
- Axis labels are 6 to 9 points six, seven, eight, nine
- Minimum font size is 6 points Minimum 6 points

IMAGE TYPES

When possible, supply vector-based files such as those produced by CorelDRAW, Adobe Illustrator or similar software.

Vector files give us maximum flexibility for sizing your figures properly.

They maintain high print-quality resolution at any size. Do not rasterize line art or text.




RESOLUTION

Photographic images should have a minimum resolution of 300 dots per inch (dpi) at final print size (see column widths above). Embedded images within a vector file should also have a minimum resolution of 300 dpi. Up sampling artwork (artificially increasing file size or resolution) will not improve quality and causes production problems.



COLOR CONVERSION

Full color artwork should be provided in RGB format (not CMYK) as your paper will be published online only.



LINE WEIGHTS

At final print size, line weights can be no thinner than .28 pt.



CLEAN SOURCE FILES

Please delete unwanted data from files. Do not hide unwanted data in masks or layers. Hidden images or data can show up in the production process. Crop out extraneous elements that are outside the image area.